Cabaletta Bio, Inc.

NASDAQ:CABA

Biotechnology

Healthcare
$1.06 +1.23%

+$0.04 today

Market cap
$227.58M
Beta
3.23
P/E (TTM)
-1.8
EPS (TTM)
-$1.57
52W Low $1.26High $4.23

Volume 4.13M

Average 3.33M

CABA Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Cabaletta Bio, Inc.NASDAQ: CABA

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue remains negative

Q1 FY2026 revenue was $0, compared with $0 a year earlier. Trailing-twelve-month revenue was $0.

Context

  • Revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Revenue history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How CABA compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
CABA Competitors
Revenue for CABA and competitors
Company Period LTM YoY 3-year CAGR
EDITEditas Medicine, Inc.LTM Mar 2026$38.69M USD+8.0%+27.1%
PRQRProQR Therapeutics N.V.LTM Mar 2026€13.44M EUR-29.2%+62.0%
IMMPImmutep LimitedFY2025A$5.04M AUD+31.3%+209.4%
HUMAHumacyte, Inc.LTM Mar 2026$2.02M USD-74.0%+9.2%
LYELLyell Immunopharma, Inc.LTM Mar 2026$31K USD-52.3%-92.5%
CABACabaletta Bio, Inc.LTM Mar 2026$0 USD——
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$0 USD-100.0%—
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$0 USD——
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$0 USD——
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$0 USD——
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$0 USD——
Peer median (excluding CABA) —-40.7%+27.1%

Competitors are the stored peer set for CABA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development32.49M39.3M55.42M97.2M142.67M
Selling, General & Admin13.82M14.84M19.24M27.94M29.57M
Operating Expenses46.31M54.14M74.66M125.14M172.24M
Depreciation & Amortization733K1.18M1.43M1.71M1.65M
EBITDA(45.56M)(51.8M)(66.25M)(113.41M)(164.21M)
EBITDA Margin—————
Operating Income(46.31M)(54.14M)(74.66M)(125.14M)(172.24M)
Operating Margin—————
Interest Income24K1.16M6.99M10.03M6.03M
Interest Expense000748K2M
Other Income / Expenses24K1.16M6.99M9.28M4.39M
Income Before Tax(46.29M)(52.98M)(67.68M)(115.86M)(167.86M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(46.29M)(52.98M)(67.68M)(115.86M)(167.86M)
Net Margin—————
EPS (Basic)(1.80)(1.81)(1.65)(2.34)(1.64)
EPS (Diluted)(1.80)(1.81)(1.65)(2.34)(1.64)
Weighted Avg Shares25.74M29.34M40.95M49.52M102.26M
Weighted Avg Shares (Diluted)25.74M29.34M40.95M49.47M102.26M

Cabaletta Bio, Inc.

NASDAQ:CABA

Intrinsic Alpha fair value

Locked

Current Price

$1.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.